Isatuximab: all 71 studies that test it

Page 1 of 1. Open to participants first (20), then studies with results posted, then the rest; newest registration first within each.

• Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma CellsNot yet recruitingNCT07732712Phase 2/3
• Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic AnemiaRecruitingNCT07714512Phase 1/2
• CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingNCT07652905Phase 2
• D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMMRecruitingNCT07624513Phase 3
• Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple MyelomaNot yet recruitingNCT07600151Phase 1/2
• Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT07479979Phase 1/2
• ELISA in Relapsed/Refractory MMRecruitingNCT06832865Phase 2
• Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering MyelomaRecruitingNCT06762769Phase 2
• Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic LeukemiaRecruitingNCT06648889Phase 2
• Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple MyelomaRecruitingNCT06517017Phase 2
• Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple MyelomaRecruitingNCT05922501Phase 2
• Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma PatientsRecruitingNCT05776979Phase 2
• International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabEnrolling by invitationNCT05669989Phase 2
• Efficacy of the antiCD38 Monoclonal Antibody Isatuximab in the Treatment of PCRA by Major ABO Mismatch After Allogeneic Hematopoietic Stem Cell TransplantationNot yet recruitingNCT05559827Phase 2
• Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple MyelomaRecruitingNCT05344833Phase 2
• A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome InhibitorNot yet recruitingNCT05298683Phase 2
• Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM PatientsRecruitingNCT05272826Phase 2
• Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT05145400Phase 2
• Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous TherapyRecruitingNCT05066607Phase 2
• Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal InsufficiencyRecruitingNCT04240054Phase 2
• Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMMActive, not recruitingNCT07217184Phase 1/2Results posted
• Isa-Pom-Dex in Elderly/Frail Subjects With RRMMActive, not recruitingNCT05911321Phase 2Results posted
• SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMMActive, not recruitingNCT05405166Phase 3Results posted
• Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)TerminatedNCT04661033Phase 2Results posted
• KRDI in Transplant-Eligible MMActive, not recruitingNCT04430894Phase 2Results posted
• Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney TransplantationTerminatedNCT04294459Phase 1/2Results posted
• Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid LeukemiaTerminatedNCT03860844Phase 2Results posted
• A Study of Isatuximab-based Therapy in Participants With LymphomaTerminatedNCT03769181Phase 1/2Results posted
• Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced MalignanciesTerminatedNCT03637764Phase 1/2Results posted
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)TerminatedNCT03555149Phase 1/2Results posted
• S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary AmyloidosisCompletedNCT03499808Phase 2Results posted
• Safety and Efficacy of Isatuximab in Lymphoblastic LeukemiaTerminatedNCT02999633Phase 2Results posted
• Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma PatientsCompletedNCT02990338Phase 3Results posted
• Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma PatientsCompletedNCT02812706Phase 1/2Results posted
• Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple MyelomaActive, not recruitingNCT06216158Phase 3
• Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple MyelomaCompletedNCT06203912Phase 1
• Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell TransplantationActive, not recruitingNCT05873205Phase 2
• Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT05804032Phase 3
• A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT05704049Phase 2
• Elimination of Minimal Residual Disease After TransplantActive, not recruitingNCT05690984Phase 2
• Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and LymphomaActive, not recruitingNCT05346809Phase 2
• A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)TerminatedNCT05284032Early Phase 1
• A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal ImpairmentStatus unknownNCT05147493Phase 2
• Isa-RVD Study in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT05123131Phase 2
• Isatuximab in Type I CryoglobulinemiaStatus unknownNCT05114109Phase 2
• Isatuximab and Bendamustine in Systemic Light Chain AmyloidosisWithdrawnNCT04943302Phase 2
• MInimal Residual Disease Adapted StrategyActive, not recruitingNCT04934475Phase 3
• Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY DiseaseTerminatedNCT04912427Phase 1
• Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04883242Phase 2
• Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04850599Phase 2
• Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT04835129Phase 2
• Rapid-infusion Isatuximab in Relapsed/Refractory Multiple MyelomaWithdrawnNCT04802031Phase 2
• A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMMActive, not recruitingNCT04786028Phase 2
• Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid MalignancyCompletedNCT04763616Phase 2
• Isatuximab as Upfront Therapy for the Treatment of High Risk AL AmyloidosisActive, not recruitingNCT04754945Phase 1
• Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMMActive, not recruitingNCT04653246Phase 2
• Isatuximab in Patients With Monoclonal Gammopathy of Renal SignificanceActive, not recruitingNCT04614558Phase 2
• Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04287855Phase 2
• Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple MyelomaActive, not recruitingNCT04270409Phase 3
• Isatuximab, Bendamustine, and Prednisone in Refractory Multiple MyelomaTerminatedNCT04083898Phase 1
• Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT04045795Phase 1
• Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT03733717Phase 1
• Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)Active, not recruitingNCT03617731Phase 3
• A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantActive, not recruitingNCT03319667Phase 3
• Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and DexamethasoneActive, not recruitingNCT03104842Phase 2
• Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)Active, not recruitingNCT02960555Phase 2
• A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple MyelomaCompletedNCT02514668Phase 1
• Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate TransplantationCompletedNCT02513186Phase 1
• Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple MyelomaCompletedNCT02332850Phase 1
• SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM PatientsCompletedNCT02283775Phase 1
• SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM PatientsCompletedNCT01749969Phase 1

← Isatuximab overview